|
Furosemide Oral Solution
» Furosemide Oral Solution contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of furosemide (C12H11ClN2O5S).
Packaging and storage
Preserve in tight, light-resistant containers.
USP Reference standards
USP Furosemide RS. USP Furosemide Related Compound A RS. USP Furosemide Related Compound B RS.
Identification
A: Ultraviolet Absorption
Solution:
6 µg per mL.
Medium:
0.01 N sodium hydroxide.
Absorptivities are not significantly different.
B:
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Minimum fill
Uniformity of dosage units
for oral solution packaged in single-unit containers:
meets the requirements.
Deliverable volume
for oral solution packaged in multiple-unit containers:
meets the requirements.
pH
noteThroughout the following procedures, protect test or assay specimens, the USP Reference Standards, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware.
Limit of furosemide related compound B
Mobile phase, System suitability solution, and Chromatographic system
Proceed as directed in the Assay.
Standard solution
Dissolve an accurately weighed quantity of USP Furosemide Related Compound B RS in Diluting solution, and dilute quantitatively, and stepwise if necessary, with Diluting solution to obtain a solution having a known concentration of about 15.0 µg per mL.
Test solution
Transfer an accurately measured portion of Oral Solution, equivalent to about 10 mg of furosemide, to a 10-mL volumetric flask, dissolve in and dilute with Diluting solution to volume, and mix.
Procedure
Separately inject equal volumes (about 10 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the areas for the major peaks: the peak response of furosemide related compound B obtained from the Test solution is not greater than the corresponding peak response obtained from the Standard solution.
Assay
Mobile phase
Prepare a filtered and degassed mixture of water, acetonitrile, and glacial acetic acid (165:35:2). Make adjustments if necessary (see System Suitability under Chromatography
Diluting solution
Prepare a mixture consisting of water, acetonitrile, and glacial acetic acid (22:22:1).
System suitability solution
Dissolve suitable quantities of USP Furosemide RS, USP Furosemide Related Compound A RS, and USP Furosemide Related Compound B RS in Diluting solution to obtain a solution containing about 0.1 mg of each per mL.
Standard preparation
Dissolve an accurately weighed quantity of USP Furosemide RS in Diluting solution, and dilute quantitatively, and stepwise if necessary, with Diluting solution to obtain a solution having a known concentration of about 1 mg per mL.
Assay preparation
Transfer an accurately measured portion of Oral Solution, equivalent to about 10 mg of furosemide, to a 10-mL volumetric flask, dissolve in and dilute with Diluting solution to volume, and mix.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of furosemide (C12H11ClN2O5S) in the portion of Oral Solution taken by the formula:
10C(rU / rS)
in which C is the concentration, in mg per mL, of USP Furosemide RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
Chromatographic Column
USP32NF27 Page 2461
Pharmacopeial Forum: Volume No. 29(6) Page 1889
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.
|